Legend Biotech (LEGN) Non-Current Deferred Tax Liability (2019 - 2021)

Legend Biotech has reported Non-Current Deferred Tax Liability for 3 years, with the latest figure at $22.8 million in Q4 2021.

• For the quarter ending Q4 2021, Non-Current Deferred Tax Liability fell 35.05% year-over-year to $22.8 million; the trailing twelve-month figure through Dec 2021 stood at $22.8 million (down 35.05% YoY), and the FY2021 full-year result was $22.8 million, down 35.05% from the prior year.
• Non-Current Deferred Tax Liability for Q4 2021 stood at $22.8 million, down from $35.0 million in the prior quarter.
• The five-year high for Non-Current Deferred Tax Liability was $47.7 million in Q4 2019, with the low at $22.8 million in Q4 2021.
• Historically, Non-Current Deferred Tax Liability has averaged $35.2 million across 3 years, with a median of $35.0 million in 2020.
• Annual changes were most pronounced in 2020 — Non-Current Deferred Tax Liability slipped 26.54% — and 2021, when it plunged 35.05%.
• Legend Biotech's Non-Current Deferred Tax Liability stood at $47.7 million in 2019, then fell by 26.54% to $35.0 million in 2020, then sank by 35.05% to $22.8 million in 2021.
• The last three Non-Current Deferred Tax Liability figures came in at $22.8 million (Q4 2021), $35.0 million (Q4 2020), and $47.7 million (Q4 2019), per Business Quant data.